Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
40 hedge funds and large institutions have $203M invested in Verona Pharma in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 5 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
8% more funds holding
Funds holding: 37 → 40 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.21% less ownership
Funds ownership: 7.91% → 7.71% (-0.21%)
13% less capital invested
Capital invested by funds: $234M → $203M (-$31.3M)
88% less call options, than puts
Call options by funds: $4K | Put options by funds: $33K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$4.9M |
| 2 |
Citigroup
New York
|
+$2.88M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.22M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$133K |
| 5 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.74M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$1.45M |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$118K |
| 4 |
QSS
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
|
-$92K |
| 5 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
-$58K |
VRNA Hedge Fund Activity: Q3 2021 in Review
40 of the 5,705 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q3 2021, worth a combined $203M — down 13% from $234M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VRNA positions and 5 closed out — a net gain of 3 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was Fairmount Funds Management, adding an estimated $4.9M. The largest seller was Vivo Capital, cutting an estimated $1.74M.
- 40 institutional investors held Verona Pharma (VRNA) as of Q3 2021, up from 37 in Q2 2021.
- Funds reported $203M of Verona Pharma stock for Q3 2021, down 13% quarter-over-quarter.
- 8 funds opened new Verona Pharma positions in Q3 2021 and 5 closed out, a net change of +3 holders.
- The largest Verona Pharma buyer in Q3 2021 was Fairmount Funds Management, an estimated $4.9M added.
- The largest Verona Pharma seller in Q3 2021 was Vivo Capital, an estimated $1.74M sold.
Based on aggregated 13F filings for Q3 2021.